India has long been the focus of the world for clinical research particularly since 2005. The market has been always every investors’ focus of attention on account of India’s massive population, large patient pool from various races, cost arbitrage, wide spectrum of diseases and availability of English speaking technical expertise in rising numbers.

The Indian clinical research industry growth and its forecasted growth can be attributed to the two factors. First, patent expirations of 140 products (worth $ 87575.2 million sales in 2010) by 2027 has given rise to Indian clinical research companies conducting bioequivalence studies both for Indian companies wanting to market their drugs in the western region as well as for foreign companies particularly the US.

Second, the phenomenal growth anticipated in Indian clinical trial market, which Frost & Sullivan forecast to grow by a 15 percent CAGR during 2010-2015.

As per Table 1, maximum numbers of patent expirations have taken place in 2012 (25 patents expired) and 2014 (18 patents expired) both in terms of value of sales and number of products. The year 2015 will see the highest value of patent expirations with 25 patents being expired.

ALSO READ: US FDA import alerts: Deciphering the right message

The patent expirations post 2015 would be moderate in terms of patent expirations both in terms of value and number of products with less than 10 products facing patent expiration. The year 2020 would be the year with the highest number of patent expirations (8 products). The highest vales of patent expirations would be achieved post 2015 would be in the years 2020, 2023, 2026 and 2027.

ReadMore